Lantheus Holdings, Inc. Forecasted to Post Q2 2022 Earnings of $0.64 Per Share (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) – Jefferies Financial Group upped their Q2 2022 EPS estimates for shares of Lantheus in a research note issued on Wednesday, May 18th. Jefferies Financial Group analyst Z. Weiner now expects that the medical equipment provider will earn $0.64 per share for the quarter, up from their prior estimate of $0.63. Jefferies Financial Group also issued estimates for Lantheus’ Q3 2022 earnings at $0.62 EPS and FY2022 earnings at $2.79 EPS.

Lantheus (NASDAQ:LNTHGet Rating) last issued its earnings results on Friday, April 29th. The medical equipment provider reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.51. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The company had revenue of $208.90 million for the quarter, compared to analyst estimates of $165.30 million. During the same period in the prior year, the firm earned $0.05 earnings per share. Lantheus’s revenue for the quarter was up 125.8% on a year-over-year basis.

Several other brokerages also recently issued reports on LNTH. StockNews.com started coverage on Lantheus in a report on Thursday, March 31st. They set a “hold” rating for the company. SVB Leerink upped their price target on Lantheus from $34.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, February 24th. B. Riley assumed coverage on Lantheus in a report on Monday, May 9th. They set a “buy” rating and a $91.00 price target for the company. Truist Financial upped their price objective on Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. Finally, Zacks Investment Research upgraded Lantheus from a “sell” rating to a “hold” rating and set a $74.00 price objective for the company in a research note on Tuesday, May 3rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $83.50.

Shares of NASDAQ:LNTH opened at $63.29 on Friday. The company has a quick ratio of 1.64, a current ratio of 1.83 and a debt-to-equity ratio of 0.31. Lantheus has a twelve month low of $19.30 and a twelve month high of $69.74. The stock’s 50 day moving average is $58.87 and its 200-day moving average is $40.25.

A number of institutional investors and hedge funds have recently modified their holdings of LNTH. Vanguard Group Inc. lifted its holdings in Lantheus by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider’s stock worth $317,595,000 after purchasing an additional 1,422,269 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Lantheus in the 1st quarter valued at about $71,663,000. Polar Asset Management Partners Inc. raised its holdings in shares of Lantheus by 70.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,513,058 shares of the medical equipment provider’s stock valued at $38,855,000 after acquiring an additional 624,459 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Lantheus by 24.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 2,978,498 shares of the medical equipment provider’s stock valued at $76,488,000 after acquiring an additional 588,392 shares in the last quarter. Finally, Soleus Capital Management L.P. raised its holdings in shares of Lantheus by 43.5% in the 4th quarter. Soleus Capital Management L.P. now owns 1,764,627 shares of the medical equipment provider’s stock valued at $50,980,000 after acquiring an additional 534,800 shares in the last quarter. 97.14% of the stock is currently owned by institutional investors and hedge funds.

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $63.27, for a total transaction of $632,700.00. Following the sale, the chief financial officer now owns 135,893 shares of the company’s stock, valued at approximately $8,597,950.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gerard Ber sold 1,277 shares of the stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $58.19, for a total value of $74,308.63. Following the sale, the director now directly owns 32,703 shares in the company, valued at approximately $1,902,987.57. The disclosure for this sale can be found here. Insiders have sold a total of 135,171 shares of company stock valued at $7,054,840 in the last quarter. 1.60% of the stock is owned by corporate insiders.

Lantheus Company Profile (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Further Reading

Earnings History and Estimates for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.